| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2679147 | Primary Care Diabetes | 2010 | 4 Pages |
Abstract
Exenatide use in type 2 diabetes is limited in routine clinical practice. We examined a cross-section of 90 patients. Mean weight and HBA1c were 114.9 ± 20.6 kg, 10.3 ± 2.1% at initiation; 108.0 ± 15.3 kg (p < 0.0001), 9.0 ± 2.1% (p < 0.001) at 3 months; 109.2 ± 18.2 kg (p < 0.0001), 9.5 ± 2.3% (p = 0.08) at 6 months. Exenatide appears effective in reducing HBA1c and weight.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
B. Natarajan, M. Edavalath, J. Davies, L. Jenkins, N. Marshall-Richards, D. Evans, D.E. Price, S.C. Bain, J.W. Stephens,